TABLE 4

In vivo drug interaction studies involving rosuvastatin and sulfasalazine indicating at least partial contribution by BCRP

Object	Object Dose^{^a}	Precipitant	Precipitant Therapeutic Class	Precipitant Dose^{^a}	% Change in AUC^{^b}	Reference
Sulfasalazine	2-g SD	Curcumin	Food products	2-g SD	220	Kusuhara et al., 2012
	500-mg SD	Pantoprazole	Proton pump inhibitors	40-mg SD	83^{^c}	Adkison et al., 2010
	100-μg SD	Curcumin	Food products	2-g SD	83	Kusuhara et al., 2012
Rosuvastatin	10 mg QD × 10 days	Cyclosporine	Immunosuppressants	75 to 200 mg BID (stable dose for at least 2 mo)	610^{^d}	Simonson et al., 2004
	10-mg SD	Atazanavir + ritonavir	Protease inhibitors	300 mg atazanavir + 100 mg ritonavir QD × 6 days	210	Busti et al., 2008
	20 mg QD × 7 days	Lopinavir + ritonavir	Protease inhibitors	400 mg lopinavir + 100 mg ritonavir BID × 7 days	110	Kiser et al., 2008
	10-mg SD	Eltrombopag	Platelet-stimulating agents	75 mg QD × 5 days	55	Allred et al., 2011
	10-mg SD	Elvitegravir + cobicistat	AIDS treatments	150 mg elvitegravir + 150 mg cobicistat QD × 10 days	40	Custodio et al., 2014
	10-mg SD	Tipranavir + ritonavir	Protease inhibitors	500 mg tipranavir + 200 mg ritonavir BID × 11 days	37	Pham et al., 2009

BID, twice daily; QD, once daily; SD, single dose.
↵^a The route of administration was oral in all cases.
↵^b Values were extracted from the Drug Interaction Database and calculated as the change in mean AUC values.
↵^c AUC change observed with 421A/C genotype and was not statistically different from control.
↵^d Change in AUC was calculated using healthy historical controls.